Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs probiotic vs bismuth for irritable bowel syndrome
IRCT20190524043688N1Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifaximin and bismuth subsalicylate in irritable bowel syndrome (IBS) (3 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoints: Abdominal pain, Bloating and 2 more. Started Dec 2021; status: completed.
02
Drugs
rifaximinbismuth subsalicylate
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20190524043688N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190524043688N1.